CIENCIAS FARMACÉUTICAS
Fachbereich
Hospital del Mar
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital del Mar (10)
2024
-
Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry
Therapeutic Advances in Gastroenterology, Vol. 17
-
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
2021
-
Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu
Journal of Clinical Medicine, Vol. 10, Núm. 19
-
Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42
2020
-
Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn’s disease
United European Gastroenterology Journal, Vol. 8, Núm. 9, pp. 1056-1066
2019
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620
2008
-
Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI
Enfermedades Infecciosas y Microbiologia Clinica
-
Recommendations for antibiotic monitoring in ICU patients
Farmacia Hospitalaria
2007
-
Sucesos adversos en cirugía general y de aparato digestivo en los hospitales españoles
Cirugia Espanola, Vol. 82, Núm. 5, pp. 268-277